Bioceres Crop Solutions (BIOX)
NASDAQ:BIOX
Want to see BIOX full AI Analyst Report?
BIOX Stock Chart & Stats
$0.44
$0.16(2.36%)
At close: 4:00 PM EST
$0.44
$0.16(2.36%)
Day’s Range― - ―
52-Week Range$0.31 - $5.00
Previous CloseN/A
Volume111.91K
Average Volume (3M)1.08M
Market Cap
$21.16M
Enterprise Value$250.54M
Total Cash (Recent Filing)$12.58M
Total Debt (Recent Filing)$239.46M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding63,228,237
10 Day Avg. Volume1,709,433
30 Day Avg. Volume1,077,044
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.07
Price to Sales (P/S)0.85
P/FCF Ratio8.00
Enterprise Value/Market Cap11.84
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda-24.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$307.10M
Bulls Say, Bears Say
Bulls Say
Executive AppointmentAppointment of Ezequiel Simmermacher as chief financial officer brings operational and business development experience that could strengthen financial discipline and strategic execution.
Management StrategyManagement's disciplined cost controls and business realignment are improving operational efficiency and support the company's transition to a more sustainable business model.
Product Mix And MarginsHigher sales of seed treatment packs, which carry structurally higher margins than downstream grains, have lifted overall profitability and improved margin profiles.
Bears Say
Litigation RiskA court ruling against the company in creditor litigation raises the risk of enforced remedies that could constrain operational flexibility and access to credit.
Refinancing ExposureA court finding of default on the notes could require refinancing of roughly $107 million of debt, creating immediate liquidity pressure and potential for higher financing costs.
Segment Sales PressureCrop Protection revenue weakness, driven by tight credit conditions and election-related uncertainty, is weighing on segment revenues and gross margins.
Bioceres Crop Solutions News
BIOX FAQ
What was Bioceres Crop Solutions’s price range in the past 12 months?
Bioceres Crop Solutions lowest stock price was $0.31 and its highest was $5.00 in the past 12 months.
What is Bioceres Crop Solutions’s market cap?
Bioceres Crop Solutions’s market cap is $21.16M.
When is Bioceres Crop Solutions’s upcoming earnings report date?
Bioceres Crop Solutions’s upcoming earnings report date is Sep 03, 2026 which is in 68 days.
How were Bioceres Crop Solutions’s earnings last quarter?
Bioceres Crop Solutions released its earnings results on May 11, 2026. The company reported -$0.157 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.107.
Is Bioceres Crop Solutions overvalued?
According to Wall Street analysts Bioceres Crop Solutions’s price is currently Overvalued.
Does Bioceres Crop Solutions pay dividends?
Bioceres Crop Solutions does not currently pay dividends.
What is Bioceres Crop Solutions’s EPS estimate?
Bioceres Crop Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioceres Crop Solutions have?
Bioceres Crop Solutions has 63,228,237 shares outstanding.
What happened to Bioceres Crop Solutions’s price movement after its last earnings report?
Bioceres Crop Solutions reported an EPS of -$0.157 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -16.943%.
Which hedge fund is a major shareholder of Bioceres Crop Solutions?
Currently, no hedge funds are holding shares in BIOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioceres Crop Solutions
Bioceres Crop Solutions Corp. (BIOX) is a company dedicated to enhancing agricultural output through a diverse range of solutions. Its operations are organized into three principal divisions. The Seed and Integrated Products segment is responsible for creating and bringing to market cutting-edge seed technologies, genetic material, biotechnological innovations, and specialized seed coatings. Under its Crop Protection segment, the company formulates, manufactures, and distributes a comprehensive array of products, including Rizoderma, various adjuvants, therapeutic agents, weed killers, insect eradicators, fungal treatments, and pest lures. The Crop Nutrition unit focuses on the development, production, and distribution of inoculants, bio-stimulants, and both organic and micro-granular fertilizers. A notable offering from Bioceres is HB4, an innovative seed technology engineered for drought resistance. The enterprise maintains a significant presence across several countries, including Argentina, Uruguay, France, and South Africa, alongside broader international operations. Established in 2001, the firm's main offices are situated in Rosario, Argentina. Bioceres Crop Solutions Corp. functions as a subsidiary entity under the umbrella of Bioceres LLC.
BIOX Company Deck
BIOX Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call outlined decisive strategic actions (new CFO hire, asset-light shift in seeds, cost controls, liability management) and one segment showing revenue growth (Crop Nutrition). However, these positives were outweighed by material near-term financial deterioration: a 23% revenue decline, 30% fall in gross profit, adjusted EBITDA turning negative, a $10M net loss, a large Pro Farm-related noncash impairment (~$179M), ongoing litigation with debt acceleration risk, and constrained liquidity. Management is pursuing remedies and operational stabilization, but significant legal and financial headwinds dominate the near-term outlook.View all BIOX earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.07% Mutual Funds
9.46% Other Institutional Investors
88.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---